Icahn School of Medicine at Mount Sinai, New York, New York.
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Pract Radiat Oncol. 2019 Jul-Aug;9(4):e400-e406. doi: 10.1016/j.prro.2019.02.009. Epub 2019 Feb 22.
The management of multiple myeloma (MM) has evolved over the past 20 years, secondary to novel biologic therapeutics. Radiation therapy remains an important intervention in the management of painful lytic bone lesions. However, the currently used radiation therapy regimens were developed in the pre-biologic therapy era. The goal of this study is to assess the effects of dose and fractionation in pain control for patients with MM in the modern era.
We conducted a retrospective study based on data collected from patients who received radiation therapy at our institute between 2007 and 2017. A total of 130 patients (266 treatment sites) were included in this study. Univariate Cox proportional hazards models were used to analyze the association of risk of pain recurrence with treatment characteristics and compute the hazard ratios (HRs).
The median follow-up time was 14 months. Patients who received a total dose of 20 to <30 Gy (including 20 Gy) had a significantly lower probability of pain recurrence when compared with those who received <20 Gy (HR, 0.36; 95% confidence interval, 0.14-0.94; P = .0365). There was no statistically significant difference in treatment response or pain recurrence between the different fraction numbers and sizes. However, we noted a trend indicating lower pain recurrence in the group that received 6 to 10 fractions of radiation therapy (P = .06). Among the most commonly used regimens, 8 Gy in a single fraction resulted in a statistically significant increased chance of pain recurrence compared with 20 Gy in 10 fractions and a borderline statistically significant increased chance of pain recurrence when compared with 30 Gy in 10 fractions.
Radiation therapy remains highly effective at managing lytic bone lesions in patients with MM, and 6- to 10-fraction treatment courses are equally as effective as longer courses at treating these lesions. Treatment with 20 Gy in 10 fractions resulted in a significantly lower probability of pain recurrence when compared with 8 Gy in 1 fraction.
在过去的 20 年中,由于新型生物治疗药物的出现,多发性骨髓瘤(MM)的治疗方法有了很大的发展。放射治疗仍然是治疗溶骨性骨病变疼痛的重要干预手段。然而,目前使用的放射治疗方案是在生物治疗前时代开发的。本研究的目的是评估在现代时代接受放射治疗的 MM 患者的剂量和分割在疼痛控制方面的效果。
我们基于 2007 年至 2017 年在我们研究所接受放射治疗的患者数据进行了回顾性研究。共有 130 名患者(266 个治疗部位)纳入本研究。单变量 Cox 比例风险模型用于分析疼痛复发的风险与治疗特征的关系,并计算风险比(HR)。
中位随访时间为 14 个月。与接受<20 Gy 总剂量的患者相比,接受 20 至<30 Gy(包括 20 Gy)总剂量的患者疼痛复发的概率显著降低(HR,0.36;95%置信区间,0.14-0.94;P=0.0365)。不同分割次数和大小的治疗反应或疼痛复发之间无统计学差异。然而,我们注意到接受 6 至 10 次放射治疗的患者组疼痛复发的可能性较低(P=0.06)。在最常用的方案中,单次 8 Gy 与 10 次 20 Gy 相比,疼痛复发的几率显著增加,与 10 次 30 Gy 相比,疼痛复发的几率有边缘统计学意义增加。
放射治疗仍然是治疗 MM 溶骨性骨病变的高度有效方法,6-10 次治疗与较长疗程治疗这些病变同样有效。与单次 8 Gy 相比,10 次 20 Gy 治疗可显著降低疼痛复发的概率。